Stocksigma LogoStocksigma Logo

Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit

Biocon Limited announced on 25th Sep'26 that its Malaysian insulin manufacturing facility received UK MHRA approval for its new drug product fill-finish

Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit

Biocon Ltd 路 Others (Uncategorized) 路 25 Sept 2026, 2:03 pm

Biocon Malaysia Secures UK MHRA Approval for Semglee Fill-Finish Unit Biocon Limited announced on 25th Sep'26 that its Malaysian insulin manufacturing facility received UK MHRA approval for its new drug product fill-finish unit for Semglee (insulin glargine). This follows an earlier regulatory clearance obtained from the European Medicines Agency (EMA) in Jul'26 for the same fill-finish line, strengthening the company's global supply capabilities for European and UK markets.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements